Abstract

TENESACA, Joselyn Sánchez  and  PEREZ, Edison Galarraga. Tumor markers CA125, He4, ROME index in ovarian cancer. Vive Rev. Salud [online]. 2022, vol.5, n.15, pp.927-936.  Epub Dec 23, 2022. ISSN 2664-3243.  https://doi.org/10.33996/revistavive.v5i15.199.

Ovarian cancer is a public health problem for which there are no standardized screening methods; however, Ca125, He4 and Rome index markers are of great value in the diagnosis and prognosis of this pathology. Objective. To analyze the behavior of tumor markers Ca125 and He4 and Rome index in the prediction of malignancy in patients with ovarian masses. Materials and Methods. The laboratory results of 112 women attended at Hospital General Ambato were taken for serum Ca125, He4 and their corresponding calculation of the Rome index. They were divided into premenopausal and postmenopausal, malignant and benign groups. Results. Analysis of the results defined the relationship of Ca 125 and He4 with the diagnosis of ovarian cancer with a confidence level of 95% and value of p<0.05. The probability of differentiating ovarian cancer from benign processes for Ca125, He4 and Rome index was 93.33%, 84.4 and 99.7, respectively. Conclusions. The best predictor of malignancy is the Rome index. Elevated serum He4 values were found to be higher for postmenopausal patients. Further studies are needed to support a standardized screening method for ovarian cancer.

Keywords : Ca-125 antigen; Temozolomide; Rome index; Ovarian Neoplasms; Malignancy.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )